2013
Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides.
Huang J, Cowper S, Moss J, Girardi M. Case experience of 308-nm excimer laser therapy compatibility with PUVA and oral bexarotene for the treatment of cutaneous lesions in mycosis fungoides. Journal Of Drugs In Dermatology 2013, 12: 487-9. PMID: 23652902.Peer-Reviewed Case Reports and Technical NotesConceptsExcimer laser therapyOral bexaroteneLaser therapyMycosis fungoides lesionsMinimal side effectsMF plaquesLocal erythemaMycosis fungoidesTreatment regimenCutaneous lesionsMF lesionsHistologic resolutionSide effectsTherapyBexaroteneLesionsUltraviolet ARegimenPUVAPatientsTreatmentPlaquesCase experienceFungoidesErythema
2008
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryTetrahydronaphthalenesConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunology
2003
Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow
Girardi M, Knobler R, Edelson R. Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematology/Oncology Clinics Of North America 2003, 17: 1391-1403. PMID: 14710891, DOI: 10.1016/s0889-8588(03)00106-0.Peer-Reviewed Original ResearchConceptsLow side effect profileSide effect profilePotential novel strategyMechanism of actionImmunosuppressive medicationsExtracorporeal photochemotherapyEffect profileTransplant rejectionTreatment of cancerClinical recordsRole of ECPClinical studiesT cellsTreatment considerationsModern therapeuticsTreatmentNovel strategyGVHDMedicationsAutoimmunityCTCLMalignancyECPTherapyCancer
1995
Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes
Girardi M, Herreid P, Tigelaar R. Specific Suppression of Lupus-Like Graft-Versus-Host Disease Using Extracorporeal Photochemical Attenuation of Effector Lymphocytes. Journal Of Investigative Dermatology 1995, 104: 177-182. PMID: 7829872, DOI: 10.1111/1523-1747.ep12612741.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAscitesAutoimmune DiseasesDisease Models, AnimalFemaleGlomerulonephritisGraft vs Host DiseaseGraft vs Host ReactionImmunotherapy, AdoptiveKidneyLupus Erythematosus, SystemicMiceMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAPUVA TherapyT-LymphocytesVaccinationConceptsSystemic lupus erythematosus-like diseaseB6D2F1 recipientsDisease initiationD2 cellsAntinuclear antibody titerLupus-like graftProgression of graftVersus Host DiseaseSystemic lupus erythematosusC3H/HeJ xDBA/2 splenocytesHost diseaseLupus erythematosusEffector lymphocytesClinical manifestationsClinical parametersHistologic evidenceAntibody titersKidney diseaseAscites formationB6D2F1 miceInterleukin-2T cellsC57BL/6 xComplex antigens